Abstract 4158
Background
Tumor-associated macrophages (TAMs) constitute over 50% of the number of cells in breast malignancies. In mouse models, most TAMs in the breast cancer microenvironment behave as the M2-like phenotype, with protumor characteristics, but the roles of TAMs in human breast cancer are poorly understand. Specific TAMs related molecular mechanisms among different intrinsic molecular subtypes remain unclear. Here, we focused on studying protumor TAM markers among human breast cancer tissues: CD163, CD204, CD206 which commonly used in mouse models. We identify and explore roles of TAMs novel marker: CD204 in intrinsic molecular subtypes of breast cancer.
Methods
Expression of CD204, CD163, CD206 and clinical outcome of CD204 were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Potential Kyoto Encyclopedia of Genes and Genomes (KEGG) and HALLMARK pathways regulated by CD204 were studied using Gene Set Enrichment Analysis (GSEA). We used CIBERSOT to estimate the immune contextures regulated by CD204 among different subtypes and the correlations of CD204 and immune suppressive molecules were also analyzed.
Results
Compared to CD163, CD206, only CD204 was found upregulated in breast cancer compared to the normal tissue, associated with poor OS, RFS, and DMFS. The expression of CD204 was different between 4 subtypes. CD204 was involved in immune system-related pathways including innate and adaptive immunity among all subtypes. Numerous special pathways were also found influenced by CD204: tumor metabolism-related pathways in luminal A, Hippo and TGF-β signaling pathways in luminal B, cell cycle process in HER-2 amplified, and RIG-I-like receptor signaling pathway in basal-like subtype. Strong correlations between CD204 and immune cells especially for protumor populations were displayed, and most immunosuppressive molecules: HIF1A, FAP, IL10, PDCD1/CD274, CTLA4, HAVCR2, positive correlated with CD204 expression in all subtypes.
Conclusions
CD204 could become an applicable marker of TAMs in human breast cancer. These findings contribute to better understanding and managing of TAMs in different subtypes of breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jinhai Tang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3630 - Results of phase 1 clinical trial of high doses of Seleno-L-methionine (SLM) in sequential combination with Axitinib in previously treated and relapsed clear cell renal carcinoma (ccRCC) patients
Presenter: Yousef Zakharia
Session: Poster Display session 3
Resources:
Abstract
2356 - Safety and Efficacy of CDX-014 , an Antibody-Drug Conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced Renal Cell Carcinoma
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
1028 - SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz).
Presenter: Begona P. Valderrama
Session: Poster Display session 3
Resources:
Abstract
2293 - Effect of Antacid Intake on the Therapeutic Efficacy of Sunitinib (SUN) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts): a Sub-Analysis of the STAR-TOR Registry
Presenter: Katrin Schlack
Session: Poster Display session 3
Resources:
Abstract
1451 - Randomized phase 3 trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN Renal 101 Japanese subgroup analysis
Presenter: Motohide Uemura
Session: Poster Display session 3
Resources:
Abstract
4399 - Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
Presenter: Jindrich Finek
Session: Poster Display session 3
Resources:
Abstract
1344 - Combination therapy with checkpoint inhibitors for first-line treatment of advanced renal cell carcinoma: A systematic review and meta-analysis of randomized controlled trials
Presenter: Kyaw Thein
Session: Poster Display session 3
Resources:
Abstract
3462 - A phase II trial of TKI induction followed by a randomized comparison between nivolumab or TKI continuation in renal cell carcinoma (NIVOSWITCH)
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
5268 - Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC)
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
4235 - First results of safety profile of nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC) in NIVES Study
Presenter: Cristina Masini
Session: Poster Display session 3
Resources:
Abstract